Prognostic significance of combined preoperative platelet-to-lymphocyte ratio and lymphocyte-to-monocyte ratio in patients undergoing surgery with stage IB non-small-cell lung cancer

Chen, Yongqiang; Wang, Weidong; Zhang, Xuewen; Yu, Xiangyang; Xi, Kexing; Wen, Yang; Wang, Gongming; Feng, Xiaoli

doi:10.2147/cmar.s177320

Cited by 33 publications

(30 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The present study has the limitations of being a single-centre retrospective study; also, although the preoperative testing that was used to obtain the ratios was the same for all patients, the ndings have not been validated in an independent cohort. The appropriate cut-off point for the ratio is di cult to establish, but according to our results, the value with the greatest sensitivity and speci city was 2.5; values above or below this showed signi cant differences in overall survival and disease-free survival, in line with other published studies [15][16][17]24,25].…”

Section: Discussionsupporting

confidence: 88%

Prognostic Value of the Preoperative Lymphocyte-to-monocyte Ratio for Survival After Lung Cancer Surgery

Ramos

Macı́a

Navarro-Martín

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: The aim of this study was to assess the effect of the lymphocyte-to-monocyte ratio (LMR), neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in patients with lung cancer treated with radical surgery on overall survival (OS), and disease-free survival (DFS).Methods: We performed a retrospective review of patients with lung cancer who prospectively underwent radical resection between 2004 and 2012. Prior to surgery, blood samples were taken as part of preoperative workup. The inflammatory markers studied were absolute values of lymphocytes, monocytes, neutrophils and platelets, with subsequent calculation of the ratios. Median follow-up was 52 months. Results: 268 patients underwent surgery, of whom 218 (81.3%) were men. Mean age was 62.9 ± 8.7 years. A lymphocyte-to-monocyte ratio ≥ 2.5 was independently associated with longer disease-free survival (hazard ratio [HR] 0.476 (0.307–0.738), p=0.001) and longer overall survival (HR, 0.546; 95% CI: 0.352-0.846; p=0.007), in models adjusted by age, sex, stage, and type of resection. No other systemic inflammatory marker showed a significant association. Conclusion: Preoperative lymphocyte-to-monocyte ratio is an independent prognostic factor in terms of overall survival and recurrence-free survival in patients with surgically resected early stage lung cancer.

show abstract

Section: Discussionsupporting

confidence: 88%

Prognostic Value of the Preoperative Lymphocyte-to-monocyte Ratio for Survival After Lung Cancer Surgery

Ramos

Macı́a

Navarro-Martín

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Chen et al confirmed preoperative values of the above ratios in patients with IB stage, operated on due to NSCLC. The multi-factor analysis revealed prognostic values of LMR and PLR ratios in patients with this disease stage (11). Results of our study indicate that the PLR ratio is characterised with the highest preoperative prognostic value.…”

Section: Discussionmentioning

confidence: 51%

Prognostic value of neutrophil-to-lymphocyte, platelet-to-lymphocyte and lymphocyte-to-monocyte ratio ratios in patients operated on due to non-small cell lung cancer

et al. 2019

View full text Add to dashboard Cite

Background: The aim of the study was to determine a prognostic value of the neutrophil to lymphocyte ratio (NLR), the platelet to lymphocyte ratio (PLR) and the lymphocyte to monocyte ratio (LMR) ratios for survival of patients, operated on due to non-small cell lung cancer (NSCLC). Methods: The study was conducted on 532 patients, operated on due to NSCLC, in stages IA-IIIA. A total of 174 females and 358 males, aged 36-84 years (the mean age: 63.6 years) were included in the study. The following factors were subject to a statistical analysis, conducted for determination of potential prognostic values of NLR, PLR and LMR ratios: age, sex, nicotinism, the number of leukocytes, neutrophils, monocytes, platelets, histopathological diagnosis, T category, N category, the Charlson comorbidity index (CCI), kind of surgery, patient survival. Results: The single-factor analysis revealed a relationship between NLR, PLR and LMR values, CCI values, the number of monocytes and the length of survival. The multi-factor analysis confirmed that for patients with expected 2-year survival, PLR above 138 (P=0.0008) is another negative prognostic factor, apart from the stage of the neoplastic disease and CCI above 4. For 5-year survival, such a relationship was not observed. Conclusions: The PLR ratio is an independent and significant prognostic factor for expected, over 2-year survival of patients operated on due to NSCLC.

show abstract

“…Pretreatment NLR is associated with the clinical outcomes of several therapeutic interventions in NSCLC patients, such as the response to platinum-based first-line chemotherapy in metastatic NSCLC patients, and the prognosis in operable NSCLC patients 27 , 28 . Moreover, inflammatory indices, including NLR, PLR, and LMR, are potential prognostic markers for lung cancer patients 29 – 32 . Our multivariate analysis demonstrated that high baseline NLR is an independent factor associated with poor PFS and OS.…”

Section: Discussionmentioning

confidence: 99%

Significance of inflammatory indexes in atezolizumab monotherapy outcomes in previously treated non-small-cell lung cancer patients

Katayama

Yamada

Chihara

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Cancer immunotherapy, including atezolizumab monotherapy, is a promising alternative strategy for patients with advanced non-small-cell lung cancer (NSCLC). Several inflammatory indices have been reported as potential biomarkers regarding the effectiveness of various treatments. This study aimed to analyze the efficacy of atezolizumab monotherapy using baseline inflammatory markers in NSCLC patients. We retrospectively enrolled 81 NSCLC patients who received atezolizumab monotherapy at six different medical institutions in Japan. The Cox proportional hazards model was used to assess the impact of the clinical variables, including inflammatory indexes, on clinical outcomes. Median progression-free survival (PFS) and overall survival (OS) were 60 days and 252 days, respectively. The objective response rate was 7.4%, and the disease control rate was 54.3%. Patients with high neutrophil to lymphocyte ratio (NLR), low lymphocyte to monocyte ratio (LMR), and/or high platelet to lymphocyte ratio (PLR), at baseline, demonstrated substantially shorter PFS and OS compared to those with a low NLR, high LMR, and/or low PLR. The multivariate analysis demonstrated that a high baseline NLR was substantially associated with short PFS and short OS. Our retrospective observations suggest that inflammatory indices may be a potential negative prognostic factor of atezolizumab monotherapy outcomes in NSCLC patients.

show abstract

Prognostic significance of combined preoperative platelet-to-lymphocyte ratio and lymphocyte-to-monocyte ratio in patients undergoing surgery with stage IB non-small-cell lung cancer

Cited by 33 publications

References 43 publications

Prognostic Value of the Preoperative Lymphocyte-to-monocyte Ratio for Survival After Lung Cancer Surgery

Prognostic Value of the Preoperative Lymphocyte-to-monocyte Ratio for Survival After Lung Cancer Surgery

Prognostic value of neutrophil-to-lymphocyte, platelet-to-lymphocyte and lymphocyte-to-monocyte ratio ratios in patients operated on due to non-small cell lung cancer

Significance of inflammatory indexes in atezolizumab monotherapy outcomes in previously treated non-small-cell lung cancer patients

Contact Info

Product

Resources

About